Fulcrum Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Fulcrum Therapeutics

31/07/2026 09:13

Fulcrum Therapeutics Inc FULC.OQ reported a quarterly adjusted loss of 47 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -28 cents.  The mean expectation of seven analysts for the quarter was for a loss of 22 cents per share. Wall Street expected results to range from -31 cents to -4 cents per share.
Reported revenue was zero​; analysts expected zero. 
Fulcrum Therapeutics Inc's reported EPS for the quarter was a loss of 34 cents​.
The company reported a quarterly loss of $26.18 million.
Fulcrum Therapeutics Inc shares had risen by 1.6% this quarter and lost 67.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 22.2% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and 2 "sell" or "strong sell." 
Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $3.50, about 6.3% below its last closing price of $3.72
This summary was machine generated from LSEG data July 31 at 08:13 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.22
-0.47
Missed
Mar. 31 2026 
-0.30
-0.25
Beat
Dec. 31 2025 
-0.31
-0.31
Met
Sep. 30 2025 
-0.29
-0.31
Missed